Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
Sumitomo Dainippon Pharma will make its third attempt for a PIII trial of its atypical antipsychotic lurasidone, sold as Latuda overseas, to obtain data to seek approval in Japan for the treatment of schizophrenia, President Masayo Tada revealed on October…
To read the full story
Related Article
- Latuda to Finally Hit Japan Market on June 11
June 5, 2020
- After 3rd PIII Try, Sumitomo Dainippon Finally Files Latuda for Japan Approval
August 1, 2019
- Sumitomo Dainippon to Begin Lurasidone PIII within FY2015, 3rd Attempt for Schizophrenia Indication
December 10, 2015
- Sumitomo Dainippon to Reinstate Hara as Drug Development Head
December 2, 2015
- Sumitomo Dainippon Logs Rise in Half-Year Earnings on N. America Latuda Sales, Weak Yen
October 29, 2015
- Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
- DSP Ceases PIII Colorectal Cancer Trial for Anticancer Agent BBI608
May 27, 2014
BUSINESS
- Fycompa Generics Head for Summer Launch as Key Patent Expires
June 23, 2026
- ASKA’s Relugolix Combo Hits Primary Goal in Japan PIII Fibroid Study
June 23, 2026
- Rege Nephro Raises 1.22 Billion Yen to Advance ADPKD Drug, iPSC Kidney Program
June 23, 2026
- Japan OTC Drug Market Falls for Third Straight Month in May: Intage
June 23, 2026
- Lilly Japan Names Karla Alcazar as New President
June 22, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…